Utilizing ctDNA to Identify ADC High-Risk Populations & Predict Therapeutic Efficacy
- Leveraging ctDNA to identify high-risk patients with molecular residual disease likely to relapse without further treatment
- Reviewing changes in ctDNA levels to serve as early efficacy or pharmacodynamic markers, predicting therapy response as early as 6 weeks
- Discussing Signatera as the most extensively validated, widely used, and broadly reimbursed ctDNA MRD assay, enabling patient stratification and treatment response monitoring to accelerate clinical development